OncoSignal
Live from Open Targets Platform, fetched 2026-11-12 03:58 UTC. Every row links to its source record.

ZFHX3 zinc finger homeobox 3

ENSG00000140836 · protein coding · Open Targets profile

Transcriptional regulator which can act as an activator or a repressor. Inhibits the enhancer element of the AFP gene by binding to its AT-rich core sequence. In concert with SMAD-dependent TGF-beta signaling can repress the transcription of AFP via its interaction with SMAD2/3 (PubMed:25105025). Regulates the circadian locomotor rhythms via transcriptional activation of neuropeptidergic genes which are essential for intercellular synchrony and rhythm amplitude in the suprachiasmatic nucleus (SCN) of the brain (By similarity). Regulator of myoblasts differentiation through the binding to the AT-rich sequence of MYF6 promoter and promoter repression (PubMed:11312261). Down-regulates the MUC5AC promoter in gastric cancer (PubMed:17330845). In association with RUNX3, up-regulates CDKN1A promoter activity following TGF-beta stimulation (PubMed:20599712). Inhibits estrogen receptor (ESR1) function by selectively competing with coactivator NCOA3 for binding to ESR1 in ESR1-positive breast cancer cells (PubMed:20720010). {ECO:0000250|UniProtKB:Q61329, ECO:0000269|PubMed:11312261, ECO:0000269|PubMed:17330845, ECO:0000269|PubMed:20599712, ECO:0000269|PubMed:20720010, ECO:0000269|PubMed:25105025}.

In 13 of 15 cancers, the evidence for ZFHX3 comes mainly from mutations found in tumours

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)
00.250.50.751prostate carcinomaprostate carcinomaprostate carcinoma: somatic 0.60prostate carcinoma: germline 0.71prostate adenocarcinomaprostate adenocarcinomaprostate adenocarcinoma: somatic 0.60endometrial cancerendometrial cancerendometrial cancer: somatic 0.69Epidermal Inclusion CystEpidermal Inclusion CystEpidermal Inclusion Cyst: germline 0.66skin basal cell carcinomaskin basal cell carcinomaskin basal cell carcinoma: somatic 0.61lung carcinomalung carcinomalung carcinoma: somatic 0.61pancreatic ductal adenocarcinomapancreatic ductal adenocarcinomapancreatic ductal adenocarcinoma: somatic 0.61thyroid gland papillary carcinomathyroid gland papillary carcinomathyroid gland papillary carcinoma: somatic 0.61endometrial endometrioid adenocarcinomaendometrial endometrioid adenocarcinomaendometrial endometrioid adenocarcinoma: somatic 0.61carcinoma of liver and intrahepatic bil…carcinoma of liver and intrahepatic biliary tractcarcinoma of liver and intrahepatic biliary tract: somatic 0.61kidney neoplasmkidney neoplasmkidney neoplasm: somatic 0.61hemangioblastomahemangioblastomahemangioblastoma: somatic 0.61HER2 positive breast carcinomaHER2 positive breast carcinomaHER2 positive breast carcinoma: somatic 0.61pancreatic neuroendocrine tumorpancreatic neuroendocrine tumorpancreatic neuroendocrine tumor: somatic 0.61lymphoid neoplasmlymphoid neoplasmlymphoid neoplasm: somatic 0.61

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

PROTAC
UniProt Ubiquitination, Database Ubiquitination

gnomAD loss of function constraint: o/e 0.15046000480651855 (upper bound 0.19460999965667725). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of ZFHX3's approved or late-stage drugs in the last three years.

No terminated, withdrawn or suspended trials of ZFHX3's drugs are registered

All 0 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

DrugTypeHighest stageIndicationsSource records
No drugs or clinical candidates recorded.